KDM1A and small cell lung carcinoma: Furthermore, Hiatt et al. confirmed that pharmacologic LSD1 inhibition with Bomedemstat in small-cell lung cancer (SCLC) models promoted antigen presentation and sensitized tumors to immune checkpoint blockade [110].